Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...

The field of traditional medicine, with its deep historical roots, offers a multitude of natural compounds with potential therapeutic benefits. Lately, ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to ...

Recovery from deadly influenza infection may hinge on helping the lungs heal in addition to stopping the virus, according to ...

In this week’s edition of InnovationRx, we look at the biotech deal frenzy, Recursion’s incoming CEO, the infant formula ...

MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

Despite a recent capital raise, Shelton-based antiviral drug developer NanoViricides Inc. disclosed it does not have enough cash to fund operations beyond mid-February and will need additional ...

The rollout of the US government's Covid-19 test-to-treat program is underway, with in-pharmacy clinics ordering shipments of Covid-19 antiviral medications, and some locations expecting to offer the ...

Scientists were pleased when they learned more about how the common cold gains a foothold in the body, identifying key cellular checkpoints that are important targets of the virus.